FDA says PTC's marketing application insufficient, shares slip

(Reuters) - PTC Therapeutics Inc's marketing application for its muscle disorder drug was not sufficient to merit a review, the U.S. Food and Drug Administration said, pushing the company's stock down about 40 percent before the bell.